ABSTRACT A beneficial effect of verapamil on left ventricular relaxation has been reported in patients with hypertrophic cardiomyopathy. The effect of 0.1 mg/kg intravenous verapamil on left ventricular relaxation and diastolic mechanics was studied in 10 patients with hypertrophic cardiomyopathy and 13 patients with aortic stenosis. M mode echocardiograms and left ventricular high-fidelity pressure measurements were obtained simultaneously in patients at rest and 10 to 15 min after verapamil. The time constant of left ventricular pressure decay (T; in msec) and the pressure intercept (PB; in mm Hg) were calculated from left ventricular pressure and negative dP/dt during isovolumetric relaxation with the use of a linear regression analysis. Left ventricular early and mean diastolic filling rates as well as diastolic pressure-diameter relationships before and after verapamil were determined from simultaneous echocardiographic and pressure measurements. After verapamil heart rate, left ventricular peak systolic pressure, and maximum and minimum dP/dt remained unchanged in both groups. Left ventricular end-diastolic pressure increased significantly from 15 to 17 mm Hg (p < .02) in patients with aortic stenosis but did not change in those with hypertrophic cardiomyopathy. However, the time constant T decreased significantly from 79 to 60 msec (p < .001) in patients with hypertrophic cardiomyopathy but increased significantly from 53 to 68 msec (p < .025) in those with aortic stenosis. Parallel to the decrease in time constant, early (5.3 vs 7.3 cm/sec, p < .05) and mean (3.0 vs 4.3 cm/sec, p < .06) diastolic lengthening rate increased in patients with hypertrophic cardiomyopathy after verapamil. In contrast, early (7.7 vs 7.6 cm/sec, p = NS) and mean (4.3 vs 4.2 cm/sec, p = NS) diastolic lengthening rate remained unchanged in patients with aortic stenosis. The diastolic pressure-diameter relationship did not change in either group after verapamil. Cycle efficiency of the left ventricular pressure-diameter loop was significantly decreased in patients with hypertrophic cardiomyopathy when compared with that in those with aortic stenosis (71% vs 80%; p < .01), but improved significantly from 71% to 77% (p < .02) in patients with hypertrophic cardiomyopathy and remained unchanged in those with aortic stenosis (80% vs 80%) after verapamil. We conclude that verapamil improves left ventricular relaxation in patients with hypertrophic cardiomyopathy but delays relaxation in those with aortic stenosis. The absence of changes in the hemodynamic determinants of left ventricular relaxation suggests an intrinsic although opposite effect of verapamil on the myocardium in patients with primary and secondary myocardial hypertrophy. The beneficial effect of verapamil in those with hypertrophic cardiomyopathy seems to be related to improved relaxation and diastolic filling rather than to changes in passive elastic chamber properties. This improvement in relaxation and diastolic filling can be explained by an increase in cycle efficiency with a decrease in left ventricular asynchrony. A beneficial effect of verapamil is not observed in patients with secondary myocardial hypertrophy due to aortic stenosis. 
intravenously administered verapamil on left ventricular relaxation and diastolic mechanics in patients with primary and secondary myocardial hypertrophy. The reaction of the myocardium to calcium blockade might help in differentiating between these two types of hypertrophy.
Patients and methods
Twenty-three patients were included in the present study. Ten patients with hypertrophic cardiomyopathy (mean age 46 years, range 32 to 65) and 13 patients with aortic stenosis (mean age 51 years, range 31 to 69) underwent diagnostic cardiac catheterization. Seven of the 23 patients were women. Nine of 10 patients with hypertrophic cardiomyopathy and 11 of 13 patients with aortic stenosis were symptomatic. Patients in both groups were in New York Heart Association functional class II (median). All patients were in sinus rhythm and the duration of the QRS complex did not exceed 0.11 sec.
Right and left heart catheterization was performed in all 23 patients. Informed consent was obtained from all. Premedication consisted of 10 mg chlordiazepoxide (Librium) given orally 1 hr before the procedure. The left ventricular outflow tract gradient was determined from simultaneous left ventricular and aortic pressure measurements. Postextrasystolic potentiation was used to study dynamic obstruction in patients with hypertrophic cardiomyopathy and to differentiate between obstructive and nonobstructive forms. Thermodilution techniques7 were used to quantify accompanying mitral regurgitation in patients with hypertrophic cardiomyopathy, and to quantify aortic regurgitation in patients with aortic stenosis. Left ventricular highfidelity pressure was measured with a transseptally introduced No. 7F Millar micromanometer-angio catheter.8 The micromanometer was calibrated by superimposing the high-fidelity pressure tracing on the conventional pressure tracing. A peripheral lead of the standard electrocardiogram and the phonocardiogram were recorded together with the high-fidelity pressure tracing and the M mode echocardiogram (figures 1 and 2).
M mode echocardiography was carried out with an echocardiograph Electronics for Medicine V 3280 interfaced to a VR-12 oscillograph. The echocardiographic recordings (figures 1 and 2) were made with a 2.25 MHz transducer with the patient in the anteroposterior or slight right anterior decubitus position.9 The echocardiographic and pressure tracings were digitized by hand on an electronic digitizer (Numonics) interfaced to a PDP 11/34 computer equipped with a printer-plotter (Versatec). The resolution of the digitizer is 0.25 mm at a paper speed of 100 mm/sec. The following variables were calculated and printed out by the computer 130 times per cardiac cycle: left ventricular internal chamber diameter, left ventricular posterior wall thickness, left ventricular high-fidelity pressure, and left ventricular dP/dt. Interobserver variability has been shown to be small9 and was 1.2% for left ventricular end-diastolic chamber diameter, 6 . 1% for left ventricular end-diastolic wall thickness, and 6.6% for peak systolic wall stress (n = 32). dP/dt was calculated from left ventricular high-fidelity pressure by digital differentiation with a five-point formula.'0
The left ventricular pressure-internal chamber diameter loop was plotted in all patients and cycle efficiency was calculated according to the technique of Gibson and Brown.1 Cycle efficiemzy was defined as the ratio of the loop area to that area of the rectangle that the pressure-diameter loop enclosed (figure 3).
Ten patients with normal left ventricular function and simultaneous echocardiographic and pressure recordings served as control subjects9 for cycle efficiency measurements. A cycle efficiency from 76% to 92% (mean 85 + 6%) was considered to be Vol. 74 , No. 3, September 1986 normal (figure 4). In four of the 23 patients no echocardiograms of good quality were obtained (patients 3, 9, 17, and 18) ence, the Scheffe procedure was applied. Statistical comparisons of diastolic pressure-diameter coordinates before and after verapamil were carried out by two-way analysis of variance for two treatment (control and verapamil) groups. The diastolic pressure-diameter coordinates are displayed as mean + 1 sem in figure 7.
Results
Representative analog recordings from a patient with hypertrophic cardiomyopathy and from one with aortic stenosis before and after verapamil are shown in figures 1 and 2, respectively.
Hemodynamic data ( 
reported a significant decrease in left ventricular contractility, which is known'3 '`to decrease the rate of relaxation. Furthermore, at the maximum vasodilation subvalvular obstruction might have been augmented in the study of TenCate et al., " although peak systolic pressure had decreased significantly. Thus, the beneficial effect of verapamil might have been masked by the short-term negative inotropic and vasodilative effects of the drug.
In accordance with most studies published in the literature the salutary effect of the calcium-channel blocker seems to be related to improved muscle inacti- ties of the heart muscle. However, the extrinsic factors can be influenced quite a lot by the administration of calcium-channel blockers, since changes in preload and afterload can lead to a baseline shift of the pressure-diameter curve`9 due to an acute reduction in intrapericardial volume and a decrease in pericardial pressure. Other extrinsic factors that may affect passive elastic properties are isovolumetric relaxation, ventricular interaction, coronary perfusion, and intrathoracic pressure. Acute myocardial ischemia has been shown to be associated with an increase in myocardial stiffness, 14' 16 which is fully reversible after termination of myocardial ischemia. Since two of the patients with hypertrophic cardiomyopathy had coronary artery disease, the administration of verapamil could explain an improvement in left ventricular relaxation and diastolic function due to improved subendocardial blood flow. However, diastolic function remained unchanged in these two patients after verapamil and the improvement in relaxation did not seem to be due to coronary artery disease because (1) subjects without coronary artery disease (n = 8) and the two patients with disease had a similar improvement in the rate of relaxation and diastolic filling after verapamil (the time constant T decreased from 82 to 62 msec, p < .001, and £m increased from 3.3 to 4.9 cm/sec, p = NS, in the eight subjects without coronary artery disease) and (2) 11  10  8  15  14  33  21  15  8  8  16  19  13  15  7   12  20  20  13  11  13  16  12  33  29  18  8   13  13  7  15  16  36  22  15  10  12  20  20  21  17  7  -J   153  144  126  133  139  190  116  129  128  89  135  26   -259  155  187  267  188  180  203  174  145  241  184  195  226  200  38   1278  1319  1622  2122  1465  1585  1002  1731  1510  889  1452  357   2016  1617  1720  2132  1674  1278  1317  2460  1522  1965  1561  1870  1402  1733  344   NS   NS   265  164  194  248  189  186  188  184  139  235  188  202  228  200  35  K..   NS   NS   2147  1409  1752  2490  1465  1197  1277  2506  1378  1762  1510  1460  1341  1669  444   1859  2033  2156  1946  2066  1581  1554  1826  1860  1899  1692  1697  1650  1832 evaluated the effect of intravenous verapamil on left ventricular relaxation, diastolic filling, and passive diastolic pressure-diameter relationships using simultaneous echocardiographic and high-fidelity pressure measurements (figure 2). In contrast to the patients with hypertrophic cardiomyopathy we observed an impairment of left ventricular relaxation in patients with aortic stenosis after the administration of verapamil (figure 5), whereas diastolic filling remained within normal limits before and after verapamil, although there were considerable variations in these measurements.
This response to verapamil is in contrast to the bene- since it has been demonstrated in other patients with coronary artery disease.20 However, this was not the case in our two patients; in fact, the rate of relaxation increased after verapamil and We and fm improved only moderately (table 3) . The 11 patients with aortic stenosis who did not have coronary artery disease also had an increase in the time constant T (from 55 to 70 msec, p < .05) and a lack of change in We (7.6 vs 7.9 cm/sec, p = NS) and em(4.6 vs 4.4 cm/sec, p = NS; table 3). Thus, the presence of coronary artery disease in two patients with aortic stenosis did not influence the conclusions of the present study with respect to the effect of verapamil on relaxation and diastolic filling in patients with secondary myocardial hypertrophy.
Aortic regurgitation might have also influenced left ventricular relaxation in patients with aortic stenosis since relaxation is not fully isovolumetric in the presence of valvular regurgitation. Three patients had no regurgitation and another four only mild regurgitation (< 20%). Six patients had moderate aortic regurgitation, and four of these had an aortic valve area of more than 1.0 cm2. Since the administration of verapamil may alter aortic regurgitation and therefore influence the relaxation process, we divided patients with aortic stenosis into two subgroups: those with mild or no regurgitation (AS 1) and those with moderate aortic regurgitation (AS2). In both subgroups the time constant T increased after administration of verapamil, in AS 1 from 51 to 63 msec ( shown6 to increase contractility but to delay ventricular relaxation. Increased intracellular calcium availability has been hypothesized to occur in patients22 and in Syrian hamsters23 with hypertrophic cardiomyopathy. A decrease in intracellular calcium availability due to the administration of verapamil would, therefore, explain an improved rate of relaxation in patients with hypertrophic cardiomyopathy. This concept of increased calcium availability probably does not apply to patients with pressure overload hypertrophy,4 because the response to calcium blockade in patients with aortic stenosis is different.
(3) Verapamil is associated with a negative inotropic effect resulting in prolonged muscle inactivation and decreased speed of relaxation. This effect is, however, suppressed in patients with hypertrophic cardiomyopathy, since the speed of relaxation is increased after verapamil. However, the negative inotropic effect may influence relaxation in patients with aortic stenosis, because left ventricular end-diastolic pressure increases significantly after verapamil and maximum dP/dt decreases slightly, although not significantly. Since increased calcium availability seems to be unlikely in patients with aortic stenosis, this mild negative inotropic effect may cause the delay in relaxation in patients with secondary myocardial hypertrophy.
(4) The administration of verapamil could improve asynchronous wall motion in patients with hypertrophic cardiomyopathy because asymmetric hypertrophy of the left ventricle with normal and hypertrophied muscle areas could influence regional inactivation.
Calcium blockade might therefore act differently on the normal and the hypertrophied muscle; for example, verapamil prolongs relaxation of the normal muscle but enhances relaxation of the hypertrophied muscle, resulting in more uniform relaxation of the left ventricle with a decrease in the time constant T in patients with hypertrophic cardiomyopathy. This hypothesis is strongly supported by the observation that cycle efficiency is improved after verapamil in patients with hypertrophic cardiomyopathy but not in those with aortic stenosis ( figure 4) .
Limitations of the study. M mode echocardiography has some specific limitations that need to be addressed. Rotation and translation of the heart affect the dimen- conditions remained essentially unchanged in the present study, a change in the basic determinants of the time constant T seems not to be responsible for the observed decrease in T after verapamil in patients with hypertrophic cardiomyopathy.
In conclusion, we compared the effect of verapamil on left ventricular relaxation, diastolic filling, and passive diastolic properties in patients with hypertrophic cardiomyopathy and those with aortic stenosis. There was an opposite reaction of the left ventricle in patients with primary and secondary hypertrophy: verapamil improved relaxation in those with hypertrophic cardiomyopathy but delayed relaxation in those with aortic stenosis. We conclude that the beneficial effect of verapamil in patients with hypertrophic cardiomyopathy is due to improved inactivation and asynchrony, whereas the effect in patients with aortic stenosis is probably due to a mild negative inotropic action.
